comparemela.com
  1. Home
  2. Live Updates
  3. Olympia Phase - Breaking News

Latest Breaking News On - Olympia phase - Page 4 : comparemela.com

AstraZeneca : Lynparza Recommended For Approval In EU For High-risk Early Breast Cancer

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Merck & Co Inc. s (MRK) Lynparza or olaparib has been recommended for marketing authorization in the.

Merck co incEuropean unionEuropean medicines agencyAstrazeneca plcCommittee for medicinal products human useMedicinal productsHuman useOlympia phase

London pre-open: Stocks seen up on positive Asian cues

London pre-open: Stocks seen up on positive Asian cues
lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomNaeem aslamEuropean unionSharecast newsLava tradeImperial leatherMedicinal productsHuman useEuropean medicines agencyOlympia phaseNew england journal

Lynparza® significantly reduces risk of death in early breast cancer patients

Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.

United statesUnited kingdomCity ofAndrew tuttSusan galbraithKing college londonEuropean society for medical oncology virtual plenaryDrug administrationFrontier science technology research foundationAmerican society of clinical oncology annual meetingBreast international groupInstitute of cancer researchOlympia phaseEuropean societyMedical oncology virtualFrontier science

Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer. First PARP inhibitor to.

United statesUnited kingdomBruxelles capitaleCity ofDaiichi sankyoAndrew tuttRoy baynesSusan galbraithKing college londonNational surgical adjuvant breastUnion for international cancerEuropean society for medical oncology virtual plenaryFrontier science technology research foundationMerck co incAmerican society of clinical oncology annual meetingCompany on twitter astrazeneca

LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesUnited kingdomBruxelles capitaleCity ofJessica mcduellDaiichi sankyoAndrew tuttBrendan mcevoyRoy baynesSusan galbraithKing college londonNational surgical adjuvant breastUnion for international cancerEuropean society for medical oncology virtual plenaryFrontier science technology research foundationCompany on twitter astrazeneca

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.